Middle Molecule Find

Rulebook › V-tags › V381

V381 Cultures and endotoxin when clinically indicated

Written V0381 on the CMS-2567 and in QCOR.

Enforces 42 CFR 494.50(c)(2)(i) · Appendix H Rev. 246, page 184 · checked 12 Nov 2026

Cited on this tag? What happens after a citation · One-page sheet for the binder

The regulation

§ 494.50(c)
- Standard: Monitoring, evaluation, and reporting requirements for the reuse of hemodialyzers and bloodlines. In addition to the requirements for hemodialyzer and bloodline reuse specified in paragraphs (a) and (b) of this section, the dialysis facility must adhere to the following: (2) When clinically indicated (for example, after adverse patient reactions), the facility must – (i) Obtain blood and dialysate cultures and endotoxin levels; and…

Read 42 CFR 494.50 on the eCFR

CMS's interpretive guidance

Interpretive Guidance § 494.50(c)(2)(i)

The facility must have a standardized procedure to ensure blood and dialysate cultures and dialysate endotoxin testing are obtained in the event of a patient reaction possibly related to dialyzer reprocessing and/or reuse.

Verbatim from Appendix H Rev. 246, with CMS's headings, lists and bold. Check page 184 (the full 469-page PDF) before quoting it.